Kraig Biocraft Laboratories has filed for an expanded investment license for its operational subsidiary, Prodigy Silk, marking a decisive shift from research output to full-scale commercial delivery. The capital allocation targets facility infrastructure and processing machinery to meet initial volume commitments, following the company’s first commercial shipment of recombinant spider silk yarn to an international performance spor

Scaling high-tenacity fiber infrastructure

By operating three parallel rearing centers and expanding dedicated mulberry cultivation, the enterprise achieved consecutive output milestones, including a record single-cycle yield of nearly 2.5 metric tons of silk cocoons. Kim Thompson, CEO, states, spider silk is moving from a scientific breakthrough to a commercial material. Prodigy Silk is the engine behind that shift, and this expanded license is how we scale that engine to meet market demand.

Navigating technical scaling and supply chains

While synthetic biology promises high-tensile alternatives to petroleum-based synthetics, scaling specialized sericulture presents operational complexities. Kraig Biocraft addresses supply chain volatility by establishing localized cocoon processing near raw agricultural inputs, securing cost-competitive production for technical textiles.

Bio-engineered textile pioneer

Kraig Biocraft Laboratories develops genetically engineered, high-performance spider silk fibers using specialized recombinant silkworm technology. Focused on technical apparel, defense textiles, and athletic performance markets, the firm is scaling its production subsidiary, Prodigy Silk, to achieve sustainable commercial revenue through international sports brand partnerships.